SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias global settlement with United Therapeutics resolves their pending litigation and preserves YUTREPIA sales for PAH, while the company gives up the PH-ILD indication and faces substantial payments. Traders are cheering the reduced risk of a broader market withdrawal and speculating about a short squeeze, while skeptics worry about the lost market opportunity and financial burden.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals proposed zero-interest convertible-note offering to fund its AI data-center buildout, alongside a planned exchange of existing notes for shares, has triggered a sharp selloff amid concerns about dilution and hedging pressure. Traders debate whether the financings low cost supports long-term expansion or whether its timing and potential share issuance are damaging for current shareholders.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is drawing attention after regulators imposed a major penalty over anti-money-laundering and sanctions-compliance failures ahead of its quarterly earnings report. Traders are split between viewing the penalty as a serious blow and treating the selloff as a buying opportunity, while also debating how it may affect the earnings outlook.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohens latest substantial open-market share purchase, part of a recent series of insider buys, is driving attention, with bullish traders treating it as a vote of confidence and a potential catalyst. Others question whether the buying can sustain momentum, while discussion of the warrants exercise threshold and a possible short squeeze remains speculative.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UEC is drawing attention after a sharp selloff to a reported 52-week low, despite a production ramp and a debt-free balance sheet. Traders are divided: bulls point to uranium inventory, cash and long-term nuclear demand, while bears focus on ongoing losses, earnings pressure and the stocks continued weakness.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts rally toward record highs is drawing attention as traders focus on its Maia 300 custom AI chip plans and Azure AI demand, with some seeing stronger capacity and less reliance on outside chipmakers. Others question whether heavy AI spending and elevated valuation will pay off, while some traders flag resistance and take profits.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Twos sharp decline is being discussed against the approaching GTA VI launch, with traders debating whether anticipation and expected sales can drive a pre-release rebound. Bulls point to the franchises demand and launch window, while skeptics cite hype already priced in, limited clarity on GTA Online monetization, and risks of a sell-the-news reaction or disruption from leaks and delay fears.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Gemini 4 Argon expectations and claims of its release are driving discussion, with traders debating whether Googles AI offering can keep pace with rivals such as Meta; many are frustrated that the stock has shown a muted, choppy reaction. Optimism around AI and cloud growth is countered by concerns about rising AI spending and whether it will translate into returns ahead of earnings.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

Traders are positioning in LABD around upcoming inflation data and the Fed outlook, debating whether higher rates and yields will pressure biotech shares. Buyout-driven rebounds in XBI have challenged the bearish view, leaving the conversation focused on volatile swings and short-term trading rather than a clear sector trend.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar shares are drawing attention after Truist upgraded the stock to Buy, with traders citing stronger U.S. module-pricing prospects from import measures and capacity booked through 2028. Bullish reactions frame the selloff as an attractive entry point, while skeptics point to rate sensitivity, policy uncertainty and weaker near-term booking visibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology PR...

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI) Alone in Prostate Cancer Models

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI) Alone in Prostate Cancer Models Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell...

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation...

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol PR Newswire RAMAT-GAN, Israel, July 16, 2026 Galmed has...

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd...

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market PR Newswire RAMAT GAN, Israel, June 8, 2026 Transaction will add FDA Breakthrough...

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of...

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA...

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics Tissue Dynamics and Galmed Pharmaceuticals to Develop...

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for...

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Eocene Ltd.

GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy?

Equity

Bullish Sentiment

Hotter than expected

As expected

Cooler than expected

The September Consumer Price Index report lands Wednesday, October 14 at 8:30 AM ET, with economists forecasting headline inflation climbing to around 3.7% from August's 3.4% reading, just two weeks before the Fed's October 27-28 meeting. How will the September CPI print compare to consensus expectations? Vote and explain your reasoning in the comments.

How will the September CPI print compare to consensus expectations?

Stocktwits

Stocktwits Polls

Galmed Pharmaceuticals Ltd

$GLMD My guess is. (Come on😃 Everybody knows)  Within 1 to 2 years max. AI will be able to develop drugs that will surpass what these small/micro caps have like this company have been working on for decades. Just my opinion. CEOs like Allen are, or should be,  aware. And just keep on hanging on (Song by Vanilla Fudge I think)  For their salaries. Sorry for being negative if it comes across that way. Just my opinion. Signed: Been here since 2020 ish. Despite that. GLTA LM

James Flynn

$GLMD So basically it almost touched its 52 wk low in today's pre market, although on tiny bit volume. But like I said, I afraid, this stock is likely gonna lose a lot of valuation from uts current stage. Very challenging next 3 to 5 months. It could (just a guess) go lower than $2.00 in comong months. Sadly !

Feed

News

Sentiment

Fundamentals

Info

GLMD Galmed Pharmaceuticals Ltd

Fundamentals

Latest GLMD News